**Figure. S2.** Enhanced maturation of Runx3 KO BMDC and similar expression of TLR2 and TLR4 in WT and KO DC. *(A)* Day 11 BMDC from cultures not treated with LPS were gated as high forward scatter/CD11c⁺ cells (R2) and assessed for expression of CD80 and MHC II. Bold lines, Runx3 KO; thin lines, WT littermates. Enhanced spontaneous maturation of the KO DC is evidenced by a larger proportion of cells with high CD80 and MHC II. *(B)* Day 7 WT and KO BMDC were grown in the presence of TGF-β (10 ng/ml) and treated (bold line) or untreated (broken line) for 4h with LPS (1µg/ml) prior to FACS analysis with anti CD11c and anti MHCII. The ratio of mature MHCII⁺ (M2) DC to immature MHCII⁻ (M1) is indicated above the histogram. Note that TGF-β inhibited maturation of WT BMDC as early as 4h after LPS treatment, but failed to do so in the KO BMDC *(C)* Expression of TLR2 (left) and TLR4 (right). TLR2, isolated WT and KO splenocytes were stained with anti CD11c and anti TLR2 (PE conjugated, clone 6C2, 12-9021, eBioscience) and analyzed by FACS. CD11c⁺ DC were gated and level of TLR2 expression was measured. TLR4, day 7 WT and KO BMDC were treated for 16h with LPS (1µg/ml) before RNA extraction and RT-PCR analysis as described in Figure 3D. TLR4 was determined at 25 and 27 cycles with the primers, F: CCTGCATAGAGGTAGTTCCTA; R: TAAGCCATGCCATGCCTTG yielding a 220bp fragment.